clinical trial · NCT00610727
Staccato Prochlorperazine Single Dose PK Study
Nova Pneuma Inc.·phase1·completed·n = 54
MigraineProchlorperazine 0.5 mg IV over 5 secInhaled prochlorperazine 0.625 mgInhaled prochlorperazine 1.25 mgInhaled prochlorperazine 2.5 mgInhaled prochlorperazine 5 mgInhaled prochlorperazine 10 mgInhaled placeboProchlorperazine 10 mg IV over 5 sec
brief summary
The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of inhaled prochlorperazine
started
Aug 1, 2004
primary completion
Oct 1, 2004
completion
Oct 1, 2004
last updated
Apr 22, 2026
detailed description
The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of a single, inhaled dose of prochlorperazine (PCZ), administered as 1 or 2 puffs in healthy young volunteers.
official title
Tolerability, Safety and Pharmacokinetics of a Single Dose of Staccato™ Prochlorperazine for Inhalation in Normal, Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol